MedTrace Logo

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-04-17

No results posted yet for this study

Summary

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design To evaluate the irritation potential of MOB015B on normal skin. Single center, randomized, controlled, evaluator blinded, within-subject comparison study

Conditions

  • Erythema

Interventions

DRUG

MOB015B

Topical formulation

DRUG

0.2% SLS

Positive control

DRUG

0.9% Saline

Negative control

DRUG

MOB015B vehicle

Topical formulation

Sponsors & Collaborators

  • Moberg Pharma AB

    lead INDUSTRY

Principal Investigators

  • Jonathan S Dosik, MD · TKL Research

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2017-11-14
Completion
2017-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06369675 on ClinicalTrials.gov